Biomea Fusion, Inc. (BMEA)
| Market Cap | 91.82M +68.5% |
| Revenue (ttm) | n/a |
| Net Income | -44.95M |
| EPS | -0.74 |
| Shares Out | 72.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,358,025 |
| Open | 1.390 |
| Previous Close | 1.370 |
| Day's Range | 1.265 - 1.390 |
| 52-Week Range | 0.872 - 3.080 |
| Beta | -0.32 |
| Analysts | Buy |
| Price Target | 6.83 (+437.8%) |
| Earnings Date | May 11, 2026 |
About BMEA
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BMEA stock is "Buy." The 12-month stock price target is $6.83, which is an increase of 437.80% from the latest price.
News
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including ...
Biomea Fusion management to meet with Citizens
Citizens Happy Hour with Management.in New Orleans on June 6 hosted by Citizens.
Biomea Fusion Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing novel therapies for diabetes and obesity, focusing on menin inhibition and oral GLP-1 programs. Phase II studies target insulin-deficient and GLP-1-treated populations, with key data readouts expected in the next year.
Biomea Fusion partners with University of Leicester on obesity study
Biomea Fusion (BMEA) announced a research collaboration with the University of Leicester to evaluate its investigational menin inhibitor, icovamenib, in combination with semaglutide in obesity within ...
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking ...
Biomea Fusion Slides: Corporate presentation
Biomea Fusion has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Biomea Fusion Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The conference highlighted a root-cause approach to diabetes by restoring beta cell function, with icovamenib showing promising results in both type 1 and type 2 diabetes. BMF-650 aims to improve oral GLP-1 therapy for obesity, with key clinical milestones expected by year-end.
Biomea Fusion to Participate at Upcoming Investor Conferences
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management wi...
Biomea Fusion reports Q1 EPS (17c), consensus (19c)
As of March 31, the company had cash, cash equivalents and restricted cash of $45.1M vs. $56.2M at previous quarter end. “Across our portfolio, we continue to execute with focus…
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported it...
Biomea Fusion Quarterly report: Q1 2026
Biomea Fusion has published its Q1 2026 quarterly earnings report on May 11, 2026.
Biomea Fusion Earnings release: Q1 2026
Biomea Fusion released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced t...
Biomea Fusion Transcript: Status update
Icovamenib, a novel menin inhibitor, shows promise for both type 1 and type 2 diabetes by regenerating beta cells and offering durable glycemic control after short-term therapy. Early data indicate meaningful A1C and C-peptide improvements with a favorable safety profile.
Biomea Fusion initiated with an Outperform at Citizens
Citizens initiated coverage of Biomea Fusion (BMEA) with an Outperform rating and $9 price target The company is developing icovamenib, a covalent small-molecule menin inhibitor, which has shown the a...
Biomea Fusion Transcript: Study result
Top-line results from the COVALENT-112 trial show that icovamenib led to a 52% increase in C-peptide at 12 weeks and sustained beta cell function at 52 weeks in recent-onset type 1 diabetes, with a favorable safety profile. A phase II study will further evaluate extended dosing and combination strategies.
Biomea Fusion Press release: Study result
Biomea Fusion issued a press release on April 28, 2026, disclosing material business information to investors.
Biomea Fusion Slides: Study result
Biomea Fusion has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial
Biomea Fusion (BMEA) “announced positive 52-week results from its Phase 2 COVALENT-112 trial evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 1 diabetes. These dat...
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced...
Biomea Fusion Proxy statement: Proxy filing
Biomea Fusion filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Biomea Fusion Slides: Corporate presentation
Biomea Fusion has posted slides in relation to its latest quarterly earnings report, which was published on April 21, 2026.
Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials
Biomea Fusion (BMEA) announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes, ma...
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline 26...
Biomea Fusion Transcript: Fireside chat
Icovamenib, a novel menin inhibitor, shows promise in restoring beta cell function and reducing A1C in diabetes patients, especially those failing GLP-1 therapies. Ongoing trials aim for key data by year-end, with the potential to delay insulin dependence and reshape diabetes treatment.